Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Farnesylthiosalicylic Acid-derivatized PEI-based Nanocarrier for Improved Tumor Vaccination

Chen, Yuang and Lu, Binfeng and Li, Song (2020) Farnesylthiosalicylic Acid-derivatized PEI-based Nanocarrier for Improved Tumor Vaccination. Master's Thesis, University of Pittsburgh. (Unpublished)

[img] PDF
Restricted to University of Pittsburgh users only until 9 April 2022.

Download (985kB) | Request a Copy

Abstract

Vaccines hold huge potential for cancer immunotherapy by activating and stimulating our immune system. Cancer vaccines that make use of mutant tumor antigens represent a promising therapeutic strategy by stimulating immune responses against tumors to generate long-term anti-tumor immunity. However, vaccines have shown limited clinical efficacy in high risk cancer patients, which mostly due to the inefficient delivery. In this study, we will focus on vaccine delivery assisted by nanoparticles for cancer immunotherapy. Nanoparticle-mediated vaccination can efficiently deliver neoantigenic nucleic acids into lymphoid organs and antigen presenting cells. The intracellular release of vaccine and cross-presentation of antigens can be fine-tuned via polymer engineering. Polyethylenimine (PEI) was conjugated with farnesylthiosalicylic acid (FTS), an inhibitor of RAS signaling and the resulting amphiphilic conjugate could self-assemble to form micelles. Subsequent interaction with nucleic acids led to formation of polymer/nucleic acid complexes of well-controlled structure. Tumor transfection via PEI-FTS was much more effective than that by PEI, other PEI variants or naked DNA alone. Significant transfection was also observed in draining lymph nodes. In vivo delivery of an ovalbumin (OVA, a model antigen) expression plasmid by PEI-FTS led to a significant growth inhibition of OVA-expressing B16F10 melanoma. PEI-FTS represents a promising transfection agent for effective gene delivery to tumors and draining lymph nodes to mediate neoantigen vaccination.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: University of Pittsburgh ETD
Status: Unpublished
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Chen, Yuangyuc56@pitt.eduyuc56
Lu, Binfengbinfeng@pitt.edubinfeng
Li, Songsol4@pitt.edusol4
ETD Committee:
TitleMemberEmail AddressPitt UsernameORCID
Thesis AdvisorLi, Songsol4@pitt.edusol4
Committee ChairLi, Songsol4@pitt.edusol4
Committee MemberLu, Binfengbinfeng@pitt.edubinfeng
Committee MemberMa, XiaochaoMXIAOCHA@pitt.eduMXIAOCHA
Date: 9 April 2020
Date Type: Publication
Defense Date: 3 April 2020
Approval Date: 9 April 2020
Submission Date: 6 April 2020
Access Restriction: 2 year -- Restrict access to University of Pittsburgh for a period of 2 years.
Number of Pages: 30
Institution: University of Pittsburgh
Schools and Programs: School of Pharmacy > Pharmaceutical Sciences
Degree: MS - Master of Science
Thesis Type: Master's Thesis
Refereed: Yes
Uncontrolled Keywords: Nanoparticle, Gene delivery, PEI, Vaccine, Neoantigen
Date Deposited: 09 Apr 2020 11:43
Last Modified: 09 Apr 2020 11:43
URI: http://d-scholarship.pitt.edu/id/eprint/38554

Metrics

Monthly Views for the past 3 years

Plum Analytics


Actions (login required)

View Item View Item